Type of Spiritual Experience
A description of the experience
Belimumab (trade name Benlysta, previously known as LymphoStat-B) is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). B cells are responsible for part of the normal immune response, and also for the immune response in autoimmune diseases like systemic lupus erythematosus (SLE).
Belimumab is approved in the United States, Canada and Europe for treatment of SLE. However, the major phase III trials excluded the more severe cases of SLE with kidney and brain damage, so its effectiveness has not been demonstrated in those cases.
U.S. F.D.A. reviewers were concerned that belimumab is only "marginally" effective, and that there were more deaths in the treatment group.
Belimumab's defenders said that in addition to its modest efficiency, belimumab allowed patients to significantly reduce their use of corticosteroids.
On Dec, 08, 2016 3,860 people reported to have side effects when taking Benlysta.
Among them, 13 people (0.34%) have Hallucinations
On Oct, 10, 2015: 716 people reported to have side effects when taking Benlysta. Among them, 6 people (0.84%) have Death.
Time on Benlysta when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death66.67%33.33%0.00%0.00%0.00%0.00%0.00%